Pearl Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Redwood City CA United States (2006)
Status: Acquired by AstraZeneca (2013)

Organization Overview

First Clinical Trial
2008
NCT00880490
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pearl Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Respiratory Aspiration (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 41
  • # of Trial APIs: 10